Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03182946 · ClinicalTrials.gov registry record
Correcting Platelet Dysfunction After Traumatic Brain Injury
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 147
- Enrollment target
NCT03182946: Completed study, sponsored by Wake Forest University Health Sciences.
NCT03182946 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 147 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03182946 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 147 participants
- Enrollment target
Study Summary
This study evaluates the impact of platelet transfusion on geriatric patients with platelet dysfunction from Traumatic Brain Injury. The authors hypothesize that patients will recover better if their platelet dysfunction is corrected with platelet transfusion.
Primary Outcome
Correction of platelet inhibition measured before and after transfusion through platelet mapping thromboelastography
Interventions
- DIAGNOSTIC_TEST Platelet mapping Thromboelastography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2021-07-01 |
What the finished NCT03182946 record still lists
NCT03182946 is an observational study that tracks outcomes without assigning an intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Platelet mapping Thromboelastography is the first listed.
NCT03182946 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03182946 about?
NCT03182946 is a clinical study titled "Correcting Platelet Dysfunction After Traumatic Brain Injury". This study evaluates the impact of platelet transfusion on geriatric patients with platelet dysfunction from Traumatic Brain Injury. The authors hypothesize that patients will recover better if their platelet dysfunction is corrected with platelet transfusion.
What is the current status of trial NCT03182946?
This trial is currently completed. The enrollment target is 147 participants. The study started on 2017-10-01. Estimated completion is 2021-07-01.
What interventions are being tested in trial NCT03182946?
The interventions under investigation include: Platelet mapping Thromboelastography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03182946?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI